# US 2024/0003884 A1 · Methods and compositions using non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of hiv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003884 A1
- Document ID: US20240003884A1
- Status: Published application
- Kind: A1
- Application number: 18/251,739
- Filed: 2021-11-09
- Published: 2024-01-04
- Earliest claimed: 2020-11-10
- Assignees: The Wistar Institute of Anatomy and Biology
- Applicants: The Wistar Institute of Anatomy and Biology
- Inventors: Mohamed Abdel-Mohsen
- Web page: https://patentgrep.com/patent/US20240003884A1

## CPC

- G01N 33/56988: {HIV or HTLV}
- A61P 31/18: for HIV
- G01N 2400/00: Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N 2800/54: Determining the risk of relapse
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions are provided for the non-invasive diagnosis of likelihood of HIV remission after antiretroviral therapy (ART) interruption, prediction of time-to-viral-rebound in an HIV subject after ART interruption and prediction of the probability of viral rebound in an HIV subject after ART interruption. Methods for treating HIV subjects by increasing or decreasing expression of certain metabolites or glycans are also provided.

## Claims

### Claim 1

A diagnostic kit for the non-invasive prediction of time-to-viral-rebound in an HIV subject after antiretroviral therapy (ART) interruption comprising reagents that detect and measure the metabolites and glycans comprising:
(a) Plasma A3G3S3 glycans, Pyruvic acid, Plasma T-antigen that binds the lectic MPA, Plasma T-antigen that binds the lectin ACA, Total fucose, L-glutamic acid, and (GlcNAc)n; or
(b) IgG A2 glycans, Plasma A3G3S3 glycans, Total Fucose, Core fucose, Plasma T-antigen that binds lectin ABA, (GlcNAc)n, and L-glutamic acid.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The kit according to claim 1, wherein each reagent detects and measures a single of said metabolites and glycans.

### Claim 4 (depends on 1)

The kit according to claim 1, wherein each reagent is a lectin, optionally associated with a detectable label.

### Claim 5 (depends on 1)

The kit according to claim 1, wherein each reagent is an antibody, optionally associated with a detectable label.

### Claim 6 (depends on 1)

The kit according to claim 1, further comprising components necessary to perform a protein binding assay.

### Claim 7 (depends on 1)

The kit according to claim 1, further comprising components necessary to perform a lectin micro array, a lectin ELISA, lectin blotting, or lectin hybridization.

### Claim 8 (depends on 1)

The kit according to claim 1, further comprising components necessary to perform capillary electrophoresis or mass spectrometry.

### Claim 9

A method for predicting time-to-viral rebound in an HIV-infected subject's sample, comprising detecting and measuring the levels of the combination of metabolites and glycans comprising:
(a) Plasma A3G3S3 glycans, Pyruvic acid, Plasma T-antigen that binds the lectic MPA, Plasma T-antigen that binds the lectin ACA, Total fucose, L-glutamic acid, and (GlcNAc)n; or
(b) IgG A2 glycans, Plasma A3G3S3 glycans, Total Fucose, Core fucose, Plasma T-antigen that binds lectin ABA, (GlcNAc)n, and L-glutamic acid.

### Claim 10 (depends on 9)

The method according to claim 9, which predicts time-to-viral rebound by 74-76%.

### Claim 11

(canceled)

### Claim 12 (depends on 9)

The method according to claim 9, which predicts the probability of viral rebound with a sensitivity of 97.5%.

### Claim 13 (depends on 1, 9)

The method according to claim 9, which employs the kit of claim 1.

### Claim 14 (depends on 9)

The method according to claim 9, which employs the steps of a protein binding assay.

### Claim 15 (depends on 14)

The method according to claim 14, which employs the steps of a lectin micro array, a lectin ELISA, lectin blotting, or lectin hybridization.

### Claim 16 (depends on 9)

The method according to claim 9, which comprises capillary electrophoresis.

### Claim 17 (depends on 9)

The method according to claim 9, which comprises mass spectrometry.

### Claim 18

A method for treating an HIV-infected subject comprising increasing the in vivo level or expression of one of more of the metabolites and glycans selected from:
(a) Glychocholic acid, Taurochenodeoxycholic acid, Glycoursodeoxycholic acid, D Glucose, Ethylmalonic acid, N-Acetyl glutamic acid, Malonic acid, Ethylmalonic acid, 1, 5, Anhydro D glucitol, Kojic acid, D-ribono-1,4-lactone, Gamma aminobutyric acid GABA, Oxoglutaric acid (α-ketoglutaric acid) and L-glutamic acid, or
(b) Pyruvic acid, L-Lactic acid, Taurine, Glycerol-3-phosphate, Indole-3 lactic acid, Indole 3 pyruvic acid, Imidazole lactic acid, Glycerophospho-N-palmitoyl ethanolamine, 2-oxindole, 3-Indoxyl sulphate, Nicotinamide, and Trimethylamine N-oxide.

### Claim 19

(canceled)
